- Home
- STAI vs SCYX Comparison
STAI vs SCYX Comparison
Compare STAI & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STAI
- SCYX
- Stock Information
- Founded
- STAI 2011
- SCYX 1999
- Country
- STAI United States
- SCYX United States
- Employees
- STAI N/A
- SCYX N/A
- Industry
- STAI
- SCYX Biotechnology: Pharmaceutical Preparations
- Sector
- STAI
- SCYX Health Care
- Exchange
- STAI Nasdaq
- SCYX Nasdaq
- Market Cap
- STAI 24.6M
- SCYX 24.6M
- IPO Year
- STAI N/A
- SCYX 2014
- Fundamental
- Price
- STAI $0.40
- SCYX $0.67
- Analyst Decision
- STAI
- SCYX Strong Buy
- Analyst Count
- STAI 0
- SCYX 1
- Target Price
- STAI N/A
- SCYX $3.00
- AVG Volume (30 Days)
- STAI 1.6M
- SCYX 664.2K
- Earning Date
- STAI 09-17-2025
- SCYX 11-05-2025
- Dividend Yield
- STAI N/A
- SCYX N/A
- EPS Growth
- STAI N/A
- SCYX N/A
- EPS
- STAI N/A
- SCYX N/A
- Revenue
- STAI $1,249,524.00
- SCYX $2,932,000.00
- Revenue This Year
- STAI N/A
- SCYX $368.39
- Revenue Next Year
- STAI N/A
- SCYX $123.36
- P/E Ratio
- STAI N/A
- SCYX N/A
- Revenue Growth
- STAI 139.30
- SCYX N/A
- 52 Week Low
- STAI $0.35
- SCYX $0.57
- 52 Week High
- STAI $12.19
- SCYX $1.49
- Technical
- Relative Strength Index (RSI)
- STAI 41.26
- SCYX 56.90
- Support Level
- STAI $0.35
- SCYX $0.57
- Resistance Level
- STAI $0.42
- SCYX $0.73
- Average True Range (ATR)
- STAI 0.04
- SCYX 0.06
- MACD
- STAI -0.01
- SCYX 0.02
- Stochastic Oscillator
- STAI 28.94
- SCYX 90.36
About STAI ScanTech AI Systems Inc. Common stock
ScanTech AI Systems Inc is developing and deploying security screening systems that protect travelers and other public members from criminals, terrorists, and other bad actors. It has developed a proprietary Computed Tomography scanning system that uses fixed-gantry technology to detect explosives, weapons, narcotics, and other contraband.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.